{"id":18035,"date":"2026-07-30T12:14:37","date_gmt":"2026-07-30T12:14:37","guid":{"rendered":"https:\/\/www.eyecliniclondon.com\/blog\/?p=18035"},"modified":"2026-07-30T13:04:40","modified_gmt":"2026-07-30T13:04:40","slug":"eye-conditions-detected-tear-biomarkers","status":"publish","type":"post","link":"https:\/\/www.eyecliniclondon.com\/blog\/eye-conditions-detected-tear-biomarkers\/","title":{"rendered":"What Eye Conditions Can Tear Biomarkers Help Detect?"},"content":{"rendered":"

Tears contain proteins, lipids, enzymes, antibodies and inflammatory molecules that can change when the tear film or ocular surface is affected by disease. These substances are known as tear biomarkers and may provide additional information about inflammation, tear stability and surface damage.<\/p>\n

Tear osmolarity and MMP-9 testing may support the assessment of dry eye disease in some clinics. Most other tear biomarkers remain research tools and cannot currently diagnose a specific eye condition without your symptoms, medical history and a complete eye examination.<\/p>\n

Why Can Tears Reveal Changes in Your Eye Health?<\/h2>\n

Your tear film lies directly over the cornea and conjunctiva, so irritation, inflammation or damage affecting these tissues may alter the composition of your tears. This makes tears a potentially useful source of information about processes occurring on the ocular surface.<\/p>\n

Tear collection is also relatively simple and less invasive, but results can be influenced by factors such as blinking, reflex tearing, eye drops, contact lenses and environment. Because of this, your tear results need to be interpreted carefully alongside your symptoms and clinical examination.<\/p>\n

How Are Tear Biomarkers Measured?<\/h2>\n

A small tear sample may be collected from the edge of the lower eyelid using a test strip, absorbent material or a fine collection device. The method used depends on whether the clinician is measuring tear osmolarity, MMP-9, proteins, inflammatory molecules or another component.<\/p>\n

Tear osmolarity and point-of-care MMP-9 tests are available in some eye-care settings, although availability and clinical use vary. MMP-9 testing may indicate increased inflammatory activity, while osmolarity testing may identify an imbalance in tear concentration. Neither test can determine the underlying cause of your symptoms or confirm a specific eye condition on its own.<\/p>\n

Dry Eye Disease<\/h2>\n

Dry eye disease is the condition for which tear osmolarity and MMP-9 currently have the clearest potential clinical application. Tear osmolarity may provide information about tear-film imbalance, while MMP-9 testing may indicate increased inflammatory activity on the ocular surface.<\/p>\n

Neither test is sufficient to diagnose dry eye disease by itself. Results should be considered alongside your symptoms and clinical assessments such as tear break-up time, ocular surface staining, examination of the eyelids and meibomian glands and tear-production testing when appropriate.<\/p>\n

Different Types of Dry Eye Disease<\/h2>\n

Dry eye disease can occur in different forms, with the two main types being aqueous-deficient and evaporative dry eye. Some people may have features of both, depending on tear production and how well the tears remain on the eye surface.<\/p>\n

Types of Dry Eye Disease<\/h2>\n\n\n\n\n\n\n\n
Type<\/strong><\/td>\nWhat Happens<\/strong><\/td>\nCommon Contributing Factors<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Aqueous-deficient dry eye<\/td>\nThe eyes do not produce enough of the watery part of the tears<\/td>\nTear-gland dysfunction, ageing or autoimmune disease<\/td>\n<\/tr>\n
Evaporative dry eye<\/td>\nTears evaporate too quickly from the ocular surface<\/td>\nMeibomian gland dysfunction, eyelid disease or environmental exposure<\/td>\n<\/tr>\n
Mixed dry eye<\/td>\nReduced tear production and increased evaporation occur together<\/td>\nA combination of tear-gland and eyelid-related problems<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Meibomian Gland Dysfunction and Blepharitis<\/h2>\n

Meibomian gland dysfunction affects the oil-producing glands within the eyelids and is a major contributor to evaporative dry eye. Blepharitis causes inflammation around the eyelid margins and may occur alongside blocked glands, irritation and an unstable tear film.<\/p>\n

Research has identified changes in tear lipids, proteins and inflammatory molecules in these conditions. However, diagnosis still depends mainly on examining the eyelids, gland openings, tear film and ocular surface rather than relying on a biomarker result.<\/p>\n

Allergic Conjunctivitis<\/h2>\n

\"\"<\/p>\n

Allergic conjunctivitis can cause itching, redness, watering and eyelid swelling after exposure to triggers such as pollen, house-dust mites or animal dander. Studies have found changes in tear immunoglobulins, cytokines and other inflammatory mediators during allergic reactions.<\/p>\n

These biomarker patterns are not sufficiently specific to confirm the diagnosis alone. Your symptoms, pattern of exposure and eye examination remain the main ways of distinguishing allergy from infection, dry eye and other causes of redness or irritation.<\/p>\n

Ocular Surface Inflammation<\/h2>\n

Ocular surface inflammation can occur in dry eye disease, allergy, blepharitis, meibomian gland dysfunction, infection and several other disorders. Tear tests such as MMP-9 may indicate that inflammatory activity is present but cannot determine which condition is responsible.<\/p>\n

Inflammation may be present even when redness is limited, but symptoms such as burning or fluctuating vision are also non-specific. A slit-lamp examination and appropriate tear-film tests are needed to identify the likely cause.<\/p>\n

Sj\u00f6gren\u2019s-Related Dry Eye<\/h2>\n

Sj\u00f6gren\u2019s disease is an autoimmune condition that can reduce tear and saliva production. Severe dry eye may occur alongside dry mouth, fatigue, joint symptoms or swelling around the salivary glands.<\/p>\n

Researchers are investigating tear proteins and inflammatory markers that may help distinguish Sj\u00f6gren\u2019s-related dry eye from other forms of dry eye. These tests cannot currently confirm Sj\u00f6gren\u2019s disease alone, so diagnosis may require eye tests, blood tests, salivary assessment and specialist review.<\/p>\n

Ocular Graft-Versus-Host Disease<\/h2>\n

Ocular graft-versus-host disease can develop after an allogeneic stem-cell transplant when donor immune cells affect the eyelids, tear glands or ocular surface. Symptoms may include severe dryness, pain, light sensitivity, redness and blurred vision.<\/p>\n

Tear biomarkers are being studied as possible measures of inflammation and disease activity. Diagnosis and treatment decisions still depend on the transplant history, symptoms and detailed examination by the transplant and ophthalmology teams.<\/p>\n

Contact Lens-Related Ocular Surface Stress<\/h2>\n

Contact lenses interact directly with the tear film and may contribute to dryness, irritation or inflammation when the lens material, fit, wearing time or care routine is unsuitable. Environmental conditions and pre-existing dry eye can also affect comfort.<\/p>\n

Research has found changes in tear proteins, enzymes and cytokines in some contact lens wearers. These findings are not currently used to diagnose contact lens intolerance routinely, so assessment should focus on lens fit, corneal health, eyelids, tear stability and wearing habits.<\/p>\n

Tear-Film Changes After Eye Surgery<\/h2>\n

Cataract surgery and laser vision correction can temporarily affect corneal nerves, blinking, tear production and ocular surface inflammation. This may cause dryness, irritation or fluctuating vision during recovery.<\/p>\n

Tear biomarkers are being studied as possible ways to assess inflammation and recovery, but routine postoperative decisions still depend on symptoms and examination of the cornea, tear film and surgical result.<\/p>\n

Keratoconus<\/h2>\n

Keratoconus causes the cornea to become thinner and change shape, leading to blurred vision, irregular astigmatism and visual distortion. Corneal topography and tomography remain the main investigations used to diagnose and monitor the condition.<\/p>\n

Research has found differences in tear enzymes, proteins and inflammatory molecules in people with keratoconus. However, no tear biomarker is currently established as a routine diagnostic or monitoring test, so these findings cannot replace corneal topography, tomography or specialist assessment.<\/p>\n

Glaucoma Treatment and Ocular Surface Disease<\/h2>\n

\"\"<\/p>\n

Glaucoma affects the optic nerve and cannot be diagnosed using tear biomarkers. Diagnosis requires assessment of factors such as eye pressure, optic nerve appearance, visual fields and, when appropriate, drainage-angle and retinal nerve-fibre imaging.<\/p>\n

Long-term glaucoma eye drops can contribute to dryness, burning or ocular surface inflammation in some patients. Tear biomarkers may help researchers understand these treatment-related changes, but they do not detect or monitor damage to the optic nerve.<\/p>\n

Diabetes-Related Ocular Surface Changes<\/h2>\n

Diabetes can affect the tear film, corneal nerves and ocular surface, potentially contributing to dryness, irritation or slower healing. Researchers have identified differences in tear proteins, inflammatory molecules and other components in some people with diabetes and diabetes-related eye complications.<\/p>\n

These biomarkers remain investigational and cannot diagnose diabetic retinopathy or determine the severity of retinal damage. Diabetes-related retinal disease still requires established assessments such as a dilated retinal examination, retinal photography or optical coherence tomography when appropriate.<\/p>\n

Can Tear Biomarkers Distinguish Between Similar Eye Conditions?<\/h2>\n

Several eye conditions can cause similar symptoms, including redness, burning, watering, irritation and fluctuating vision. Dry eye disease, allergic conjunctivitis, blepharitis, infection and contact lens-related irritation may also produce overlapping inflammatory changes in the tears.<\/p>\n

A biomarker result may show that tear-film imbalance or inflammation is present, but it usually cannot identify the exact condition responsible. Your eye specialist will need to consider the pattern of your symptoms, possible triggers, eyelid health, tear-film findings and ocular-surface appearance before reaching a diagnosis.<\/p>\n

Can Tear Biomarkers Help Monitor Treatment Response?<\/h2>\n

Researchers are studying whether changes in tear osmolarity, MMP-9 and other inflammatory molecules can help show how the ocular surface responds to treatment. In selected dry-eye clinics, repeated testing may provide additional information alongside changes in symptoms and examination findings.<\/p>\n

However, biomarker levels can vary because of environmental conditions, eye-drop use, collection technique and natural changes in the tear film. Treatment decisions should therefore not be based only on whether one biomarker result rises or falls.<\/p>\n

Who May Be Offered Tear Biomarker Testing?<\/h2>\n

Tear osmolarity or MMP-9 testing may be considered when you have persistent dry-eye or ocular-surface symptoms and your clinician wants additional information about tear-film imbalance or inflammation. Testing may also be useful when symptoms and examination findings do not clearly match or when treatment response is being reviewed.<\/p>\n

These tests are not required for every patient with dry-eye symptoms, and many clinics diagnose and manage ocular-surface conditions using established examination methods. Your eye specialist can explain whether biomarker testing is available, whether it is likely to add useful information and how the result would affect your assessment.<\/p>\n

What Are the Limitations of Tear Biomarker Testing?<\/h2>\n

Tear biomarker results can be affected by many factors because your tear composition changes naturally throughout the day. Environmental conditions, eye drops, blinking patterns and the way samples are collected can all influence the measurements.<\/p>\n